New drug targets brain inflammation in early Alzheimer's – could it slow memory loss?
Disease control
Completed
This study tested an experimental drug called XPro1595 in 208 people with early Alzheimer's disease who also had signs of brain inflammation. The goal was to see if the drug could improve thinking, memory, and daily function compared to a placebo over 24 weeks. Researchers also c…
Phase: PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC